Wound was Mimedx’s largest product and service line in fiscal 2025, bringing in $276.33M of $418.63M (66%).
| Product and Service | FY 2014 | FY 2015 | FY 2016 | FY 2020 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|
| Wound | — | $205.66M | $231.00M | $276.33M | ||||
| Tissue/Other | — | — | — | — | ||||
| Hospital | $163.21M | — | — | — | ||||
| Wound Care | — | — | — | — | ||||
| Surgical | — | $115.82M | $117.88M | $142.30M | ||||
| Private Office | $77.16M | — | — | — | ||||
| Surgical, Sports Medicine Orthopedics (Sso) | — | — | — | — | ||||
| Section 351 | — | — | — | — | ||||
| Other | $27.48M | — | — | — | ||||
| Cord | — | — | — | — | ||||
| Total | $267.84M | $321.48M | $348.88M | $418.63M |
Mimedx brought in $418.63M from its two product and service lines in fiscal 2025, the year ended December 31, 2025. That was up 20.0% from $348.88M in fiscal 2024. Wound was the largest at $276.33M (66.0%), ahead of Surgical at $142.30M (34.0%).
Compared with fiscal 2024, Surgical grew 20.7% to $142.30M and Wound grew 19.6% to $276.33M.
Mimedx began breaking out Wound in fiscal 2023 and Surgical in fiscal 2023. Mimedx stopped reporting Hospital ($163.21M in fiscal 2022), Private Office ($77.16M in fiscal 2022) and Other ($27.48M in fiscal 2022) as separate lines.
Direct Customers was Mimedx’s largest revenue line in fiscal 2017, bringing in $286.74M of $321.14M (89%).
| Customer | FY 2017 |
|---|---|
| Direct Customers | $286.74M |
| Distributors | $27.43M |
| Other | $6.97M |
| Total | $321.14M |
Mimedx brought in $321.14M from its three revenue lines in fiscal 2017, the year ended December 31, 2017. Direct Customers was the largest at $286.74M (89.3%), ahead of Distributors at $27.43M (8.5%) and Other at $6.97M (2.2%).
Direct Customers was Mimedx’s largest revenue line in fiscal 2020, bringing in $240.69M of $248.23M (97%).
| Contract with Customer, Sales Channel | FY 2018 | FY 2019 | FY 2020 |
|---|---|---|---|
| Direct Customers | — | $288.80M | $240.69M |
| Sales Channel, Directly To Consumer | $343.46M | — | — |
| Distributors | — | $10.46M | $7.54M |
| Sales Channel, Through Intermediary | $15.65M | — | — |
| Total | $359.11M | $299.26M | $248.23M |
Mimedx brought in $248.23M from its two revenue lines in fiscal 2020, the year ended December 31, 2020. That was down 17.0% from $299.26M in fiscal 2019. Direct Customers was the largest at $240.69M (97.0%), ahead of Distributors at $7.54M (3.0%).
Compared with fiscal 2019, Direct Customers fell 16.7% to $240.69M and Distributors fell 27.8% to $7.54M.
Mimedx began breaking out Direct Customers in fiscal 2019 and Distributors in fiscal 2019. Mimedx stopped reporting Sales Channel, Directly To Consumer ($343.46M in fiscal 2018) and Sales Channel, Through Intermediary ($15.65M in fiscal 2018) as separate revenue lines.
Mimedx (MDXG) reports its revenue by product and service, by customer and by contract with customer, sales channel. In fiscal 2025, Wound was its largest product and service line, bringing in $276.33M (66.0% of the total), followed by Surgical at $142.30M (34.0%).
Wound was Mimedx's largest product and service line in fiscal 2025, bringing in $276.33M, or 66.0% of the $418.63M total across its two product and service lines.
Direct Customers was Mimedx's largest revenue line in fiscal 2017, bringing in $286.74M, or 89.3% of the $321.14M total across its three revenue lines.
Surgical grew faster than Wound in fiscal 2025, up 20.7% from $117.88M to $142.30M. Wound grew 19.6% to $276.33M.
Every figure comes from Mimedx's annual financial filings, as reported. Each line keeps the name Mimedx gives it, and years follow its fiscal calendar.
Mimedx's revenue by product and service goes back to fiscal 2014, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.